VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock
HENDERSON, Nev., June 5, 2023 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to Volition from the offering of approximately $16.5 million, before deducting underwriting commissions and other offering expenses payable by Volition. All … Read more